Zostavax User Fee Date Extended To May
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is extending the user fee date for Merck's zoster vaccine Zostavax by three months to May 25 in order to review additional information provided by the firm, Merck said Feb. 24
You may also be interested in...
Merck Gardasil Slated For Advisory Committee Review May 18
Vaccines & Related Biological Products committee will review HPV vaccine less than a month ahead of June 8 priority review user fee date.
Merck Gardasil Slated For Advisory Committee Review May 18
Vaccines & Related Biological Products committee will review HPV vaccine less than a month ahead of June 8 priority review user fee date.
Merck Zostavax Shingles Vaccine Safe and Effective For Adults Over 60, Committee Says
FDA's Vaccines & Related Biological Products Advisory Committee said data do not support Merck's proposed indication for adults as young as 50 years.